You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

338 Results
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab and Relatlimab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Nov 2024
Document
Document
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Nov 2024
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes

Pages